Stop Retaliating Against Whistleblowers
TAKE ACTION! Help rescind proposed firing of FDA scientist
TAKE ACTION! Help rescind proposed firing of FDA scientist
The excerpts from The New Yorker (below) may be read as a companion piece to the Atlantic article profiling Dr. John Ioannidis. However, the opening example that Lehrer uses to make the point that initial impressive positive research findings often weaken in time, perpetuates a myth about the new antipsychotics, a myth promulgated by…
Why does the Obama administration shield PhRMA companies against lawsuits by public hospitals and clinics that have been overcharged for drugs in violation of a federal law mandating reduced drug prices for clinics and hospitals that serve the poor?
Topical tacrolimus and pimecrolimus: cancer, infections—"a clearly unfavorable benefit-risk ratio"— Prescrire International 2010 ; 19 (110) : 257 English edition.
Project Paperclip was the largest and longest-running operation involving Nazis in the history of the United States, and its effects are still being felt today.
Why the tragic case of Dna Markingson and the culpability of the University of Minnesota won’t go away…
" we know how to prevent many of these patient deaths, but we don’t." WHY?
From 1991-2000 qui tam law suits accounted for only 9% of settlements with the government. But from 2001-2010, qui tam settlements comprised 67% of the billions in payouts
In 2008, 6,485 trials were conducted off shore with almost no FDA oversight. Seventy-eight percent of all human test subjects were enrolled at foreign sites.
"Prescription Drugs Associated with Reports of Violence Towards Others, " identifies 31 drugs linked to 1,527 acts of violence…
Although the FBI closed the 2001 anthrax mailings investigation in Feb. 2010, experts disagree with FBI’s conclusion: new information about the anthrax, the investigation and the suspect still continue to emerge.
The latest psychotherapy fad is "cybertherapy embraces escapism and the mechanized techniques of "virtual reality." It has been given a veneer of legitimacy by a prominent article in the New York Times "Science" section.